A Phase 1, Randomized, Double-blinded, Placebo-controlled, Dose-escalation and Dose-expansion Study to Evaluate the Safety and Immunogenicity of DelNS1-nCoV-RBD LAIV for COVID-19 in Healthy Adults
Latest Information Update: 05 Apr 2023
At a glance
- Drugs DelNS1-nCoV-RBD LAIV (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- 24 Sep 2021 Status changed from recruiting to active, no longer recruiting.
- 30 Mar 2021 Status changed from not yet recruiting to recruiting.
- 25 Mar 2021 New trial record